AN OPEN-LABEL, RANDOMIZED PROSPECTIVE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CAMPATH-1H AS AN INDUCTION AGENT IN COMBINATION WITH LOW DOSE-TACROLIMUS, LOW DOSE MMF AND REDUCED STEROID THERAPY COMPARED TO ATG-INDUCTION IN COMBINATION WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS THERAPY IN DE NOVO LUNG TRANSPLANTED PATIENTS.

Trial Profile

AN OPEN-LABEL, RANDOMIZED PROSPECTIVE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CAMPATH-1H AS AN INDUCTION AGENT IN COMBINATION WITH LOW DOSE-TACROLIMUS, LOW DOSE MMF AND REDUCED STEROID THERAPY COMPARED TO ATG-INDUCTION IN COMBINATION WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS THERAPY IN DE NOVO LUNG TRANSPLANTED PATIENTS.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Mycophenolate mofetil; Steroids; Tacrolimus
  • Indications Transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUCIA
  • Most Recent Events

    • 04 Jul 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 18 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top